论文部分内容阅读
1979年第一个氟喹诺酮类(FQNLs)药物合成后,发展十分迅速。到20世纪90年代又有司帕沙星(sparfloxacin,SPFX)、曲伐沙星(trovafloxacin,TVFX)等多种更新的FQNLs药物相继面世。FQNLs已成为处方率仅次于β-内酰胺类的抗感染药物,是一类有巨大潜力的新型抗菌药。具有抗菌谱广、抗菌作用强、药代动力学较好、口服吸收好、无特殊毒副作用的优点。临床上常用于敏感菌引起的呼吸道、泌尿道、消化道、胆道、皮肤及软组织、眼、耳、鼻、喉等部位的感染。
In 1979 the first fluoroquinolones (FQNLs) drug synthesis, the rapid development. By the 1990s, a number of newer FQNLs such as sparfloxacin (SPFX) and trovafloxacin (TVFX) have been published. FQNLs have become the new antimicrobials with great potential because they are the second most effective anti-infectives of β-lactams. Has broad antibacterial spectrum, strong antibacterial effect, better pharmacokinetics, oral absorption, no special side effects. Clinically commonly used in sensitive respiratory tract caused by bacteria, urinary tract, digestive tract, biliary tract, skin and soft tissue, eyes, ears, nose, throat and other parts of the infection.